Sartorius opens the week with a clear consensus, shares steady on Xetra
Published on 06/28/2026 at 13:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 13:03.
Sartorius (DE0006292006) starts the new week with a stable analyst consensus and a firm listing on Xetra. The German laboratory and bioprocessing specialist remains a core healthcare name in Europe, with its shares trading steadily despite broader sector volatility.
What analysts are saying today
Across major data aggregators, Sartorius is covered predominantly by European houses focusing on medtech and life sciences. A majority of analysts rate the stock from Hold to Buy, reflecting its established role as a supplier to biopharma and research laboratories worldwide.
Consensus estimates point to continued revenue growth driven by demand for bioprocessing equipment and consumables. Earnings expectations for the current year assume a moderate margin improvement as mix shifts toward higher-value solutions and service contracts.
Positioning in the healthcare peer group
Within the European healthcare segment, Sartorius competes with peers such as Merck KGaA and Lonza for bioprocessing and lab equipment budgets. Its focus on filtration, weighing and single-use technologies gives the company a clear niche in the biopharmaceutical supply chain.
Investors often compare Sartorius to these larger diversified peers when assessing valuation multiples and growth profiles. The company’s exposure to biologics manufacturing and advanced cell and gene therapy processes is seen as a structural support for long-term demand.
All news and key data on the Sartorius shares
Further articles, data points and past ad hoc releases on Sartorius are available in the dedicated topic section and via the company’s investor relations page.
The products behind the Sartorius stock
Sartorius generates its revenue primarily from laboratory balances, filtration systems and bioprocessing equipment used in pharmaceutical and biotech production. A representative product line is the Cubis II analytical balances family, which targets high-precision weighing applications in regulated laboratories.
Where the Sartorius shares trade today
The Sartorius shares (DE0006292006) trade on Xetra; as of 2026-06-28, 13:03, the latest live-verified price data were not available, so only the listing and venue can be stated here.
Key data on the Sartorius shares
- Company: Sartorius AG
- ISIN: DE0006292006
- WKN: 629200
- Ticker: SRT
- Trading venue: Xetra
- Price (as of 2026-06-28, 13:03): not live-verified
- Market cap: not live-verified
- Sector / industry: Healthcare equipment and supplies
- Index membership: MDAX
- Next earnings date: not officially scheduled
This article provides a factual snapshot of the Sartorius shares and does not contain investment advice or a recommendation to buy or sell securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
